# Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above

> **NCT05156632** · PHASE3 · WITHDRAWN · sponsor: **Sinovac Research and Development Co., Ltd.**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Medium-dosage COVID-19 Vaccine,Inactivated
- **BIOLOGICAL:** High-dosage COVID-19 Vaccine,Inactivated
- **BIOLOGICAL:** Placebo-comparator group

## Key facts

- **NCT ID:** NCT05156632
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-20
- **Primary completion:** 2023-02-20
- **Final completion:** 2023-02-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The plan has changed
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156632, "Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05156632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*